サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1425010

急性リンパ性白血病治療薬市場：用途別、薬剤別、国別、地域別- 産業分析、市場規模、市場シェア、2023-2030年予測

Acute Lymphoblastic Leukemia Therapeutics Market, By Application, By Drug, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 277 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
急性リンパ性白血病治療薬市場：用途別、薬剤別、国別、地域別- 産業分析、市場規模、市場シェア、2023-2030年予測
出版日: 2024年02月07日
発行: AnalystView Market Insights
ページ情報: 英文 277 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

急性リンパ性白血病治療薬市場規模は2022年に37億9,420万米ドルとなり、2023年から2030年にかけてCAGR 5.7%で拡大する見込みです。

急性リンパ性白血病治療薬市場-市場力学

急性リンパ性白血病の罹患率の増加および世界の骨髄生検の急増が市場需要を促進すると予想される

市場は、急性リンパ性白血病の罹患率の増加と世界の骨髄生検の急増によって成長を示しています。さらに、白血病研究への投資の高まりや、国民の間で標的治療に対する認識が高まっていることも、市場拡大の原動力となっています。しかし、規制当局の厳しい承認や副作用が課題となっています。主要治療薬の特許切れや治療費の高騰も市場の成長を制限しています。しかし、臨床試験の増加や新製品の承認は、新興国市場や先進国市場にチャンスをもたらしています。

急性リンパ性白血病治療薬市場-主要インサイト

当社のリサーチアナリストが共有した分析によると、世界の急性リンパ性白血病治療薬市場は、予測期間（2023-2030年）に約5.7％のCAGRで毎年成長すると予測されています。

急性リンパ性白血病治療薬市場は、急性リンパ性白血病の罹患率の増加と世界の骨髄生検の急増に牽引され、著しい速度で成長すると予測される

用途別では、小児科分野が2022年に最大の市場シェアを示すと予測される

薬剤別では、ハイパーCVADレジメンが2022年の主要セグメントです。

地域別では、北米が2022年の主要収益源となる

急性リンパ性白血病治療薬市場-セグメンテーション分析：

世界の急性リンパ性白血病治療薬市場は、用途別、薬剤別、地域別に区分されます。

用途に基づいて、市場は小児科と成人の2つのセグメントに分けられます。小児科領域が最も高い収益をあげており、予測期間中も主導的地位を維持すると予想されます。これは主に、小児人口の間で急性リンパ性／リンパ芽球性白血病の発症率が上昇していることに起因しています。急性リンパ性／リンパ芽球性白血病は、小児層で最も罹患率の高いがん種の1つです。さらに、小児患者は急性リンパ性／リンパ芽球性白血病治療の成功率が高く、このセグメントの優位性をさらに強固なものにしています。

市場は薬剤別に6つのセグメントに分類される：ハイパーCVADレジメン、リンカーレジメン、ヌクレオシド代謝阻害剤（クローラーやネララビンなど）、標的薬・免疫療法、CALGB 8811レジメン、オンカスパーです。これらの中で、Hyper-CVADレジメンは、ALL治療におけるその広範な利用により、2022年の急性リンパ性/リンパ芽球性白血病治療薬市場で支配的なプレーヤーとして浮上しました。Hyper-CVADレジメンは、急性リンパ性／リンパ芽球性白血病に最も頻繁に採用される治療法の1つとして広く認知されています。

急性リンパ性白血病治療薬市場-地理的洞察

地理的に、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの各地域に広がっています。これらの地域は、ビジネスをもたらす国によってさらに分けられます。

急性リンパ性白血病治療薬市場-競合情勢：

急性リンパ性白血病治療薬分野の企業は、治療の選択肢を広げるために研究開発に積極的に取り組んでいます。これらの企業は、ALLの特定の側面を標的とする新規薬剤や治療法の発見に投資し、有効性の向上と副作用の軽減を目指しています。ヘルスケア機関や学術研究センターとの連携により、臨床試験や革新的な治療法の開発が促進されています。また、特に新興市場において、これらの治療法の入手しやすさと購入しやすさを向上させるための努力も行っています。さらに、企業は患者の安全性を確保するため、規制当局の承認と厳格な品質基準の遵守を優先しています。全体的な目標は、ALL治療薬の展望を進化させ続け、この課題と闘う患者に希望とより良い転帰を提供することです。

目次

第1章 急性リンパ性白血病治療薬市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 急性リンパ性白血病治療薬の主要な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 今後の市場動向

第4章 急性リンパ性白血病治療薬業界の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 急性リンパ性白血病治療薬市場：COVID-19の影響分析

  • プレ新型コロナウイルス感染症の影響分析
  • ポスト新型コロナウイルス感染症の影響分析

第6章 急性リンパ性白血病治療薬市場情勢

  • 急性リンパ性白血病治療薬市場シェア分析、2022年
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 急性リンパ性白血病治療薬市場- 用途別

  • 概要
    • 用途別のセグメントシェア分析
    • 小児
    • 大人

第8章 急性リンパ性白血病治療薬市場- 薬剤別

  • 概要
    • 薬剤別セグメントシェア分析
    • ハイパーCVADレジメン
    • リンカーレジメン
    • ヌクレオシド代謝阻害剤（クロラーおよびネララビン）
    • 標的薬物と免疫療法
    • CALGB 8811レジメン
    • オンカスパ

第9章 急性リンパ性白血病治療薬市場- 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東とアフリカ
    • 概要
    • 中東およびアフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第10章 主要ベンダー分析- 急性リンパ性白血病治療薬業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Amgen, Inc.
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Erytech Pharma, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Kite Pharma, Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Spectrum

第11章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Acute Lymphoblastic Leukemia Therapeutics Market: Application Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Application
  • TABLE Global Acute Lymphoblastic Leukemia Therapeutics Market, by Application 2018-2030 (USD Million)
  • TABLE Acute Lymphoblastic Leukemia Therapeutics Market: Drug Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug
  • TABLE Global Acute Lymphoblastic Leukemia Therapeutics Market, by Drug 2018-2030 (USD Million)
  • TABLE Acute Lymphoblastic Leukemia Therapeutics Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Acute Lymphoblastic Leukemia Therapeutics Market, by Region 2018-2030 (USD Million)
  • TABLE North America Acute Lymphoblastic Leukemia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Acute Lymphoblastic Leukemia Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE North America Acute Lymphoblastic Leukemia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Europe Acute Lymphoblastic Leukemia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Acute Lymphoblastic Leukemia Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE Europe Acute Lymphoblastic Leukemia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Asia Pacific Acute Lymphoblastic Leukemia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Acute Lymphoblastic Leukemia Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE Asia Pacific Acute Lymphoblastic Leukemia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Latin America Acute Lymphoblastic Leukemia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Acute Lymphoblastic Leukemia Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE Latin America Acute Lymphoblastic Leukemia Therapeutics Market, by Drug, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market, by Application, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market, by Drug, 2018-2030 (USD Million)

List of Figures

  • FIGURE Acute Lymphoblastic Leukemia Therapeutics Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Application segment market share analysis, 2022 & 2030
  • FIGURE Application segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Drug segment market share analysis, 2022 & 2030
  • FIGURE Drug segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022 & 2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Acute Lymphoblastic Leukemia Therapeutics Market share and leading players, 2022
  • FIGURE Europe Acute Lymphoblastic Leukemia Therapeutics Market share and leading players, 2022
  • FIGURE Asia Pacific Acute Lymphoblastic Leukemia Therapeutics Market share and leading players, 2022
  • FIGURE Latin America Acute Lymphoblastic Leukemia Therapeutics Market share and leading players, 2022
  • FIGURE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Acute Lymphoblastic Leukemia Therapeutics Market share analysis by country, 2022
  • FIGURE Germany Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Acute Lymphoblastic Leukemia Therapeutics Market share analysis by country, 2022
  • FIGURE India Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Acute Lymphoblastic Leukemia Therapeutics Market share analysis by country, 2022
  • FIGURE Brazil Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market share analysis by country, 2022
  • FIGURE Saudi Arabia Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Acute Lymphoblastic Leukemia Therapeutics Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
目次
Product Code: ANV2210

REPORT HIGHLIGHT

Acute Lymphoblastic Leukemia Therapeutics Market size was valued at USD 3,794.2 Million in 2022, expanding at a CAGR of 5.7% from 2023 to 2030.

Acute lymphocytic/lymphoblastic leukemia is a cancer type originating from immature lymphocytes. The term "acute" denotes its rapid progression and spread throughout the body, originating in the bone marrow and swiftly infiltrating other vital organs like the liver, spleen, lymph nodes, central nervous system, and bloodstream. Symptoms may include fatigue, pallor, easy bruising, gum and nosebleeds, weight loss, shortness of breath, and loss of appetite. Multiple therapeutic approaches, including chemotherapy, are utilized in ALL treatment.

Acute Lymphoblastic Leukemia Therapeutics Market- Market Dynamics

Increasing incidence of acute lymphoblastic leukemia and a surge in global bone marrow biopsies is expected to propel the market demand

The market is witnessing growth due to the increasing incidence of acute lymphoblastic leukemia and a surge in global bone marrow biopsies. Additionally, heightened investments in leukemia research and growing awareness of targeted therapies among the population are driving market expansion. However, stringent regulatory approvals and adverse drug side effects pose challenges. Patent expirations of key treatment drugs and elevated therapy costs also limit market growth. Nonetheless, increasing clinical trials and new product approvals offer opportunities in emerging and developed markets.

Acute Lymphoblastic Leukemia Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global Acute Lymphoblastic Leukemia Therapeutics Market is estimated to grow annually at a CAGR of around 5.7% over the forecast period (2023-2030)

The Acute Lymphoblastic Leukemia Therapeutics Market is projected to grow at a significant rate driven by increasing incidence of acute lymphoblastic leukemia and a surge in global bone marrow biopsies

Based on Application, the pediatrics segment was predicted to show maximum market share in the year 2022

Based on Drug, Hyper -CVAD Regimen was the leading Segment in 2022

On the basis of region, North America was the leading revenue generator in 2022

Acute Lymphoblastic Leukemia Therapeutics Market- Segmentation Analysis:

The Global Acute Lymphoblastic Leukemia Therapeutics Market is segmented on the basis of Application, By Drug, and Region.

Based on the application, the market is divided into two segments: pediatrics and adults. The pediatrics segment generated the highest revenue, and it is expected to maintain its leading position throughout the forecast period. This is primarily attributed to the elevated incidence of acute lymphocytic/lymphoblastic leukemia among the pediatric population. Acute lymphocytic/lymphoblastic leukemia ranks as one of the most prevalent cancer types in the pediatric demographic. Furthermore, pediatric patients exhibit a higher success rate in acute lymphocytic/lymphoblastic leukemia treatments, further solidifying the segment's dominance.

The market is categorized by Drug into six segments: Hyper-CVAD Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors (such as Clolar and Nelarabine), Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, and Oncaspar. Among these, the Hyper-CVAD Regimen emerged as the dominant player in the acute lymphocytic/lymphoblastic leukemia therapeutics market in 2022 due to its extensive utilization in ALL treatment. The Hyper-CVAD Regimen is widely recognized as one of the most frequently employed therapeutic options for acute lymphocytic/lymphoblastic leukemia.

Acute Lymphoblastic Leukemia Therapeutics Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Acute Lymphoblastic Leukemia Therapeutics Market- Competitive Landscape:

Companies in the Acute Lymphoblastic Leukemia therapeutics sector are actively engaged in research and development to advance treatment options. They invest in the discovery of novel drugs and therapies that target specific aspects of ALL, aiming for improved efficacy and reduced side effects. Collaborations with healthcare institutions and academic research centers facilitate clinical trials and the development of innovative treatments. Efforts are also directed towards enhancing the accessibility and affordability of these treatments, particularly in emerging markets. Furthermore, companies prioritize regulatory approvals and adherence to stringent quality standards to ensure patient safety. Overall, their goal is to continue evolving the landscape of ALL therapeutics, offering hope and better outcomes for patients battling this challenging disease.

Recent Developments:

In May 2023, Shorla Oncology, a pharmaceutical company based in the United States and Ireland, in collaboration with EVERSANA, a leading provider of commercialization services for the life science sector, officially initiated the commercial release of Nelarabine Injection. This drug is intended for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in both adult and pediatric patients aged one year and older who have not experienced a positive response to, or have experienced relapse following treatment with, a minimum of two chemotherapy regimens.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET KEY PLAYERS

  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Erytech Pharma, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Kite Pharma, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Spectrum

GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY APPLICATION

  • Pediatrics
  • Adults

GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG

  • Hyper-CVAD Regimen
  • Linker Regimen
  • Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
  • Targeted Drugs & Immunotherapy
  • CALGB 8811 Regimen
  • Oncaspa

GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Acute Lymphoblastic Leukemia Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Acute Lymphoblastic Leukemia Therapeutics Market Snippet by Application
    • 2.1.2. Acute Lymphoblastic Leukemia Therapeutics Market Snippet by Drug
    • 2.1.3. Acute Lymphoblastic Leukemia Therapeutics Market Snippet by Country
    • 2.1.4. Acute Lymphoblastic Leukemia Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Acute Lymphoblastic Leukemia Therapeutics Key Market Trends

  • 3.1. Acute Lymphoblastic Leukemia Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Acute Lymphoblastic Leukemia Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Acute Lymphoblastic Leukemia Therapeutics Market Opportunities
  • 3.4. Acute Lymphoblastic Leukemia Therapeutics Market Future Trends

4. Acute Lymphoblastic Leukemia Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Acute Lymphoblastic Leukemia Therapeutics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Acute Lymphoblastic Leukemia Therapeutics Market Landscape

  • 6.1. Acute Lymphoblastic Leukemia Therapeutics Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Acute Lymphoblastic Leukemia Therapeutics Market - By Application

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Application, 2022 & 2030 (%)
    • 7.1.2. Pediatrics
    • 7.1.3. Adults

8. Acute Lymphoblastic Leukemia Therapeutics Market - By Drug

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug, 2022 & 2030 (%)
    • 8.1.2. Hyper-CVAD Regimen
    • 8.1.3. Linker Regimen
    • 8.1.4. Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
    • 8.1.5. Targeted Drugs & Immunotherapy
    • 8.1.6. CALGB 8811 Regimen
    • 8.1.7. Oncaspa

9. Acute Lymphoblastic Leukemia Therapeutics Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Acute Lymphoblastic Leukemia Therapeutics Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Drug, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Acute Lymphoblastic Leukemia Therapeutics Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Amgen, Inc.
    • 10.2.2. Bristol-Myers Squibb Company
    • 10.2.3. Celgene Corporation
    • 10.2.4. Erytech Pharma, Inc.
    • 10.2.5. F. Hoffmann-La Roche Ltd.
    • 10.2.6. Kite Pharma, Inc.
    • 10.2.7. Novartis AG
    • 10.2.8. Pfizer Inc.
    • 10.2.9. Sanofi
    • 10.2.10. Spectrum

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us